Therapeutics M&A Transactions

SERB Pharmaceuticals secures European and MENA rights for Hansa Biopharma's Idefirix® (imlifidase) in a €115M deal, enhancing kidney transplant options.

SERB Pharmaceuticals secures European and MENA rights for Hansa Biopharma's imlifidase, a key therapy for highly sensitized kidney transplant patients, in a €115M deal.

Private equity firms EQT and IDG Capital are in advanced talks to acquire Swiss peptide therapeutics manufacturer PolyPeptide, valued near $1.6 billion.

Neurocrine Biosciences strengthens rare disease portfolio with $2.9B acquisition of Soleno Therapeutics and its PWS treatment, VYKAT XR.

OrganaBio secures Excellos' assets, establishing a bicoastal cell therapy CDMO to address critical manufacturing and supply chain needs.

Cellular Intelligence

Cellular Intelligence acquires Parkinson's cell therapy rights from Novo Nordisk, leveraging AI for faster development and manufacturing. Backed by Khosla Ventures, CZI, SciFi VC, AMD Ventures.

Eli Lilly's $3.25B acquisition of Kelonia Therapeutics bolsters its oncology pipeline with advanced CAR-T technology. Learn about this strategic biotech deal.

Bayer's $2.45B acquisition of Perfuse Therapeutics bolsters its ophthalmology pipeline with a novel treatment for glaucoma and diabetic retinopathy.

Angelini Pharma acquires Catalyst Pharmaceuticals for $4.1B, significantly expanding its U.S. rare disease and neurological disorder footprint.

Merck strengthens its oncology pipeline by acquiring Terns Pharmaceuticals for $5.8 billion, adding a promising CML treatment candidate.